Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly ...

Nasdaq-listed shares of BriaCell Therapeutics Corp. (BCTX) traded nearly 12% higher on Wednesday after the company announced positive survival data in its Phase 2 study of Bria-IMT plus check point ...

Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ ...

Therapeutics announces new positive survival data in its Phase 2 study of Bria-IMT plus check point inhibitors, outperforming ...

The biotechnology company said its Bria-IMT plus check point inhibitors showed a 17.3-month survival rate for patients with hormone receptor-positive breast cancer, exceeding the 14.4 months of ...

BriaCell stock (TSX:BCT) is positioned to the upside after reporting phase 2 survival data for its Bria-IMT cell therapy with ...

Initiated Phase 1/2 study expansion for IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy ®, Gilead's Trop-2 directed ADC, in MTAP-deletion urothelial cancer based on preliminary ...

Trodelvy is already approved to treat advanced, pre-treated triple-negative breast cancer (TNBC) and urothelial cancer, with sales in the first half of the year almost doubling to $305 million, ...

IDEAYA Biosciences begins phase 1/2 clinical trial to evaluate IDE397 and Trodelvy combination in MTAP-deletion urothelial cancer: South San Francisco, California Monday, April 14 ...

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of ...

"We are pleased to advance the potential first-in-class clinical combination of IDE397 and Trodelvy into an initial Phase 1/2 expansion in MTAP-deletion UC based on preliminary safety and clinical ...